IXICO Full Year 2023 Earnings: Beats Expectations

IXICO (LON:IXI) Full Year 2023 Results

Key Financial Results

• Revenue: UK£6.67m (down 23% from FY 2022).
• Net loss: UK£1.18m (down by 214% from UK£1.03m profit in FY 2022).
• UK£0.024 loss per share (down from UK£0.021 profit in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

IXICO Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 6.2%.

The primary driver behind last 12 months revenue was the United States of America segment contributing a total revenue of UK£3.05m (46% of total revenue). Notably, cost of sales worth UK£3.40m amounted to 51% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to UK£2.85m (61% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of UK£259.0k. Explore how IXI's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 4.0% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom.

Performance of the British Life Sciences industry.

The company's shares are down 8.2% from a week ago.

Risk Analysis

Be aware that IXICO is showing 3 warning signs in our investment analysis and 2 of those are concerning...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.